Vericel Corporation share price today

(VCEL)

Vericel Corporation share price is $56.37 & ₹4,771.33 as on 7 Dec 2024, 2.30 'hrs' IST

$56.37

▲

-0.15

(-0.27%)

Market is closed - opens 8 PM, 09 Dec 2024

View live Vericel Corporation share price in Dollar and Rupees. Guide to invest in Vericel Corporation from India. Also see the sentimental analysis on Indian investors investing in Vericel Corporation. Get details on the Indian mutual funds that are investing in Vericel Corporation. Get Analyst recommendations and forecasts along with all the Vericel Corporation's financials.

Vericel Corporation share price movements

$55.47
$57.13
$56.37
1.61%
Downside
Day's Volatility :2.91%
Upside
1.32%
$32.31
$61.49
$56.37
42.68%
Downside
52 Weeks Volatility :47.45%
Upside
8.33%

Vericel Corporation Returns

Period	Vericel Corporation	Sector (Health Care)	Index (Russel 2000)
3 Months	28.78%	-5.7%	0.0%
6 Months	29.84%	-0.8%	0.0%
1 Year	66.92%	9.9%	0.0%
3 Years	39.04%	10.7%	-19.7%

Vericel Corporation Key Statistics

in dollars & INR

Previous Close	$56.52
Open	$56.8
Today's High	$57.125
Today's Low	$55.465
Market Capitalization	$2.9B
Today's Volume	$190.1K
52 Week High	$61.49
52 Week Low	$32.31
Revenue TTM	$226.8M
EBITDA	$3.9M
Earnings Per Share (EPS)	$0.08
PE Ratio	726.88
Profit Margin	1.56%
Quarterly Earnings Growth YOY	1.05%
Return On Equity TTM	1.54%

How to invest in Vericel Corporation from India?

It is very easy for Indian residents to invest directly in Vericel Corporation from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Vericel Corporation stock in both rupees (INR) and dollars (USD). Search for Vericel Corporation or VCEL on INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Vericel Corporation or Rupee/ Dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Vericel Corporation shares which would translate to 0.015 fractional shares of Vericel Corporation as of today. Learn more about fractional investing here.

Indians via INDmoney can now also, easily transfer and add their money to the US stocks account via INDmoney App. Click here for step by step process for the same

Indian investors sentiment towards Vericel Corporation

250%

Period: Sep 7, 2024 to Dec 6, 2024. Change in 30 Days versus previous period

Search volume for Vericel Corporation on INDmoney from India has grown in the last 30 days as on Dec 7, 2024. 250% more investors are searching Vericel Corporation in the last 30 days versus the previous period.

Global Institutional Holdings in Vericel Corporation

BlackRock Inc
16.32%
Brown Capital Management, LLC
7.75%
Vanguard Group Inc
7.06%
State Street Corp
4.92%
FMR Inc
4.81%
Amvescap Plc.
4.80%

Analyst Recommendation on Vericel Corporation

Buy

91%Buy

8%Hold

0%Sell

Based on 12 Wall street analysts offering stock ratings for Vericel Corporation(by analysts ranked 0 to 5 stars)

Based on 12 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Vericel Corporation

What analysts predicted

Upside of 9.1%

Current:

$56.37

Target:

$61.50

Insights on Vericel Corporation

Increasing Revenue
Revenue is up for the last 3 quarters, 51.28M → 57.90M (in $), with an average increase of 5.8% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -4.68M → -901.0K (in $), with an average increase of 419.6% per quarter

Vericel Corporation Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$90.9M	↑ 42.13%
Net Income	$-8.1M	↓ 52.93%
Net Profit Margin	-8.96%	↑ 18.08%

	FY19	Y/Y Change
Revenue	$117.9M	↑ 29.71%
Net Income	$-7.9M	↓ 2.8%
Net Profit Margin	-6.71%	↑ 2.25%

	FY20	Y/Y Change
Revenue	$124.2M	↑ 5.37%
Net Income	$2.9M	↓ 136.21%
Net Profit Margin	2.31%	↑ 9.02%

	FY21	Y/Y Change
Revenue	$156.2M	↑ 25.77%
Net Income	$-7.5M	↓ 360.86%
Net Profit Margin	-4.78%	↓ 7.09%

	FY22	Y/Y Change
Revenue	$164.4M	↑ 5.24%
Net Income	$-16.7M	↑ 123.65%
Net Profit Margin	-10.17%	↓ 5.39%

	FY23	Y/Y Change
Revenue	$197.5M	↑ 20.17%
Net Income	$-3.2M	↓ 80.96%
Net Profit Margin	-1.61%	↑ 8.56%

	Q2 FY23	Q/Q Change
Revenue	$45.9M	↑ 11.96%
Net Income	$-5.0M	↓ 20.78%
Net Profit Margin	-10.93%	↑ 4.52%

	Q3 FY23	Q/Q Change
Revenue	$45.6M	↓ 0.74%
Net Income	$-3.7M	↓ 27.09%
Net Profit Margin	-8.03%	↑ 2.9%

	Q4 FY23	Q/Q Change
Revenue	$65.0M	↑ 42.59%
Net Income	$13.0M	↓ 455.0%
Net Profit Margin	19.99%	↑ 28.02%

	Q1 FY24	Q/Q Change
Revenue	$51.3M	↓ 21.1%
Net Income	$-3.9M	↓ 129.72%
Net Profit Margin	-7.53%	↓ 27.52%

	Q2 FY24	Q/Q Change
Revenue	$52.7M	↑ 2.69%
Net Income	$-4.7M	↑ 21.23%
Net Profit Margin	-8.89%	↓ 1.36%

	Q3 FY24	Q/Q Change
Revenue	$57.9M	↑ 9.96%
Net Income	$-901.0K	↓ 80.76%
Net Profit Margin	-1.56%	↑ 7.33%

	FY18	Y/Y Change
Total Assets	$118.7M	↑ 117.47%
Total Liabilities	$16.5M	↓ 48.63%

	FY19	Y/Y Change
Total Assets	$153.2M	↑ 29.11%
Total Liabilities	$42.1M	↑ 156.09%

	FY20	Y/Y Change
Total Assets	$205.6M	↑ 34.18%
Total Liabilities	$71.3M	↑ 69.28%

	FY21	Y/Y Change
Total Assets	$243.7M	↑ 18.53%
Total Liabilities	$73.2M	↑ 2.66%

	FY22	Y/Y Change
Total Assets	$273.0M	↑ 12.02%
Total Liabilities	$80.7M	↑ 10.22%

	FY23	Y/Y Change
Total Assets	$353.7M	↑ 29.54%
Total Liabilities	$127.7M	↑ 58.19%

	Q2 FY23	Q/Q Change
Total Assets	$310.7M	↑ 17.21%
Total Liabilities	$111.8M	↑ 57.18%

	Q3 FY23	Q/Q Change
Total Assets	$318.1M	↑ 2.39%
Total Liabilities	$113.7M	↑ 1.76%

	Q4 FY23	Q/Q Change
Total Assets	$353.7M	↑ 11.17%
Total Liabilities	$127.7M	↑ 12.27%

	Q1 FY24	Q/Q Change
Total Assets	$356.7M	↑ 0.85%
Total Liabilities	$122.8M	↓ 3.87%

	Q2 FY24	Q/Q Change
Total Assets	$376.8M	↑ 5.66%
Total Liabilities	$133.9M	↑ 9.04%

	Q3 FY24	Q/Q Change
Total Assets	$390.4M	↑ 3.6%
Total Liabilities	$132.9M	↓ 0.69%

	FY18	Y/Y Change
Operating Cash Flow	$-412.0K	↓ 96.87%
Investing Cash Flow	$-67.0M	↑ 4338.87%
Financing Cash Flow	$58.9M	↑ 216.86%

	FY19	Y/Y Change
Operating Cash Flow	$-7.2M	↑ 1643.45%
Investing Cash Flow	$10.6M	↓ 115.84%
Financing Cash Flow	$5.3M	↓ 91.06%

	FY20	Y/Y Change
Operating Cash Flow	$17.6M	↓ 344.63%
Investing Cash Flow	$-17.2M	↓ 261.66%
Financing Cash Flow	$6.4M	↑ 22.45%

	FY21	Y/Y Change
Operating Cash Flow	$29.0M	↑ 65.26%
Investing Cash Flow	$-3.5M	↓ 79.6%
Financing Cash Flow	$9.2M	↑ 42.38%

	FY22	Y/Y Change
Operating Cash Flow	$17.7M	↓ 39.09%
Investing Cash Flow	$-36.2M	↑ 934.16%
Financing Cash Flow	$1.0M	↓ 88.61%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$10.2M	↑ 29.72%
Investing Cash Flow	$-2.4M	↓ 186.0%
Financing Cash Flow	$1.2M	↑ 1016.82%

Vericel Corporation Technicals Summary

Sell

Neutral

Buy

Vericel Corporation is currently in a neutral trading position according to technical analysis indicators.

Vericel Corporation Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Vericel Corporation	17.65%	29.84%	66.92%	39.04%	205.51%
Regeneron Pharmaceuticals, Inc.	-5.97%	-23.34%	-8.6%	17.41%	110.02%
Biontech Se	11.44%	21.29%	14.9%	-59.29%	309.79%
Alnylam Pharmaceuticals, Inc.	-7.77%	64.08%	48.09%	42.33%	108.61%
Vertex Pharmaceuticals Incorporated	-6.83%	-4.83%	31.35%	122.6%	109.65%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Vericel Corporation	726.88	726.88	0.0	0.13	0.02	0.0	NA	5.23
Regeneron Pharmaceuticals, Inc.	18.56	18.56	1.12	44.92	0.17	0.07	NA	272.04
Biontech Se	160.8	NA	0.04	-3.06	-0.02	-0.01	NA	79.73
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	-0.19	-15.01	-0.03	NA	0.25
Vertex Pharmaceuticals Incorporated	32.84	NA	1.21	0.54	-0.03	0.12	NA	60.65

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Vericel Corporation	Buy	$2.9B	205.51%	726.88	1.56%
Regeneron Pharmaceuticals, Inc.	Buy	$82.9B	110.02%	18.56	33.61%
Biontech Se	Buy	$28.5B	309.79%	160.8	-15.36%
Alnylam Pharmaceuticals, Inc.	Buy	$32.7B	108.61%	NA	-15.86%
Vertex Pharmaceuticals Incorporated	Buy	$118.4B	109.65%	32.84	-4.51%

About Vericel Corporation

about vericel founded in 1989, vericel (formerly aastrom biosciences), is dedicated to the development of patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. the company markets two cell therapy products in the united states, carticel® (autologous cultured chondrocytes), an autologous chondrocyte implant for the treatment of cartilage defects in the knee and epicel® (cultured epidermal autografts), a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. vericel is also developing maci, a third-generation autologous chondrocyte implant for the treatment of cartilage defects in the knee, and ixmyelocel-t, a patient specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy (dcm). to fulfill vericel’s mission of helping people with severe diseases and conditions rea

Organization	Vericel Corporation
Employees	314
CEO	Mr. Dominick C. Colangelo Esq.
Industry	Health Technology

Management People of Vericel Corporation

Name	Title
Mr. Dominick C. Colangelo Esq.	CEO, President & Director
Mr. Joseph Anthony Mara Jr.	CFO & Treasurer
Mr. Michael Halpin	Chief Operating Officer
Mr. Sean C. Flynn	Chief Legal Officer
Dr. Jonathan M. Hopper FRCSEd., M.B. Ch.B.	Chief Medical Officer
Mr. Jonathan D. Siegal	Principal Accounting Officer, VP & Corporate Controller
Mr. Eric Burns	Vice President of Finance & Investor Relations
Mr. Patrick J. Fowler	Senior Vice President of Corporate Development & Strategy
Mr. Patrick Helfrich	Vice President of Marketing & Commercial Strategy
Mr. Mike Gilligan	Senior Vice President of Sales

Important FAQs about investing in Vericel Corporation from India :

What is Vericel Corporation share price today?

Vericel Corporation (VCEL) share price today is $56.37.

Can Indians buy Vericel Corporation shares?

Yes, Indians can invest in the Vericel Corporation (VCEL) from India.

With INDmoney, you can buy Vericel Corporation at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Vericel Corporation at zero transaction cost.

How can I buy Vericel Corporation shares from India?

It is very easy to buy Vericel Corporation from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Vericel Corporation be purchased?

Yes, you can buy fractional shares of Vericel Corporation with INDmoney app.

What are the documents required to start investing in Vericel Corporation stocks?

To start investing in Vericel Corporation, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.